Christopher  Simon net worth and biography

Christopher Simon Biography and Net Worth

CEO of Haemonetics
Mr. Simon is President and Chief Executive Officer of Haemonetics. He joined Haemonetics and our Board in May 2016. Previously, Mr. Simon served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon was a consultant with McKinsey & Company beginning in 1993 and was the Lead Partner for McKinsey & Company’s strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the Company’s business and markets. Together with management and the Board, he was the co-architect of the strategic plan that the Company is now implementing.

What is Christopher Simon's net worth?

The estimated net worth of Christopher Simon is at least $19.07 million as of June 13th, 2022. Mr. Simon owns 213,724 shares of Haemonetics stock worth more than $19,068,455 as of November 18th. This net worth approximation does not reflect any other assets that Mr. Simon may own. Additionally, Mr. Simon receives a salary of $3,260,000.00 as CEO at Haemonetics. Learn More about Christopher Simon's net worth.

How old is Christopher Simon?

Mr. Simon is currently 60 years old. There are 5 older executives and no younger executives at Haemonetics. Learn More on Christopher Simon's age.

What is Christopher Simon's salary?

As the CEO of Haemonetics Co., Mr. Simon earns $3,260,000.00 per year. Learn More on Christopher Simon's salary.

How do I contact Christopher Simon?

The corporate mailing address for Mr. Simon and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Christopher Simon's contact information.

Has Christopher Simon been buying or selling shares of Haemonetics?

Christopher Simon has not been actively trading shares of Haemonetics during the last quarter. Most recently, Christopher Simon sold 1,148 shares of the business's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $62.60, for a transaction totalling $71,864.80. Following the completion of the sale, the chief executive officer now directly owns 213,724 shares of the company's stock, valued at $13,379,122.40. Learn More on Christopher Simon's trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 9 times. They sold a total of 33,828 shares worth more than $3,031,094.99. The most recent insider tranaction occured on July, 26th when insider Stewart W Strong sold 4,312 shares worth more than $393,038.80. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 7/26/2024.

Christopher Simon Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/13/2022Sell1,148$62.60$71,864.80213,724View SEC Filing Icon  
5/19/2022Sell2,496$59.10$147,513.60214,872View SEC Filing Icon  
5/16/2022Sell832$56.10$46,675.20191,327View SEC Filing Icon  
6/14/2021Sell1,200$59.87$71,844.00View SEC Filing Icon  
6/7/2021Sell2,715$55.09$149,569.35View SEC Filing Icon  
5/19/2021Sell1,024$55.19$56,514.56View SEC Filing Icon  
5/17/2021Sell956$55.97$53,507.32View SEC Filing Icon  
6/30/2020Sell5,084$87.79$446,324.36View SEC Filing Icon  
6/15/2020Sell47,017$87.75$4,125,741.75View SEC Filing Icon  
6/12/2020Sell1,294$89.29$115,541.26View SEC Filing Icon  
6/8/2020Sell2,920$97.03$283,327.60View SEC Filing Icon  
5/15/2020Sell1,008$100.44$101,243.52View SEC Filing Icon  
8/19/2019Sell50,869$137.43$6,990,926.67View SEC Filing Icon  
7/1/2019Sell5,008$121.79$609,924.32View SEC Filing Icon  
6/12/2019Sell1,248$109.37$136,493.76View SEC Filing Icon  
6/7/2019Sell2,834$103.38$292,978.92View SEC Filing Icon  
5/23/2019Sell24,412$99.39$2,426,308.68View SEC Filing Icon  
5/13/2019Sell57,587$94.51$5,442,547.37View SEC Filing Icon  
7/2/2018Sell5,139$89.31$458,964.09View SEC Filing Icon  
6/29/2018Sell3,595$40.39$145,202.05View SEC Filing Icon  
6/7/2018Sell1,941$92.73$179,988.93View SEC Filing Icon  
8/4/2016Buy60,000$35.00$2,100,000.00View SEC Filing Icon  
See Full Table

Christopher Simon Buying and Selling Activity at Haemonetics

This chart shows Christopher Simon's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $89.22
Low: $88.64
High: $91.43

50 Day Range

MA: $77.55
Low: $71.15
High: $93.38

2 Week Range

Now: $89.22
Low: $70.25
High: $97.97

Volume

564,400 shs

Average Volume

555,780 shs

Market Capitalization

$4.48 billion

P/E Ratio

37.02

Dividend Yield

N/A

Beta

0.32